SB17170

DRUG4 trials

Sponsors

SPARK Biopharma

Conditions

Drug Drug Interaction (DDI)IPFIdiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)PharmacodynamicsPharmacokineticsSafety IssuesSolid Tumor

Phase 1

SB17170 Phase 1 Clinical Trial in Solid Tumors

RecruitingNCT05522868

SPARK BiopharmaSolid Tumor

Start: 2022-10-17End: 2027-12-30Target: 50Updated: 2025-11-20

SB17170 Phase1 Trial in Healthy Volunteer

CompletedNCT05795192

SPARK BiopharmaPharmacodynamics, Pharmacokinetics, Safety Issues +1

Start: 2023-05-24End: 2024-03-15Updated: 2024-03-21

A Open-label, Drug-Drug Interaction With SB_MDZ in Healty Adult Subjects

CompletedNCT06846684

SPARK BiopharmaDrug Drug Interaction (DDI)

Start: 2025-03-27End: 2025-09-12Updated: 2025-11-19

Phase 2

SB17170 Phase 2 Trial in IPF Patients

RecruitingNCT06747923

SPARK BiopharmaIdiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF), IPF

Start: 2025-01-27End: 2026-10-31Target: 30Updated: 2025-11-19